Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425264 | 0.87 | PTPN11 (0.48) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL25514534 | 0.83 | PTPN11 (0.44) | PTPN11 | |
| SCHEMBL19785085 | 0.83 | PTPN11 (0.54) | PTPN11 | |
| SCHEMBL24233638 | 0.80 | PTPN11 (0.49) | PTPN11KCNH2 | |
| SCHEMBL24233619 | 0.80 | PTPN11 (0.43) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL24233651 | 0.78 | PTPN11 (0.46) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL24233656 | 0.76 | PTPN11 (0.57) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL21154870 | 0.75 | PTPN11 (0.41) | PTPN11 | |
| SCHEMBL24233646 | 0.70 | PTPN11 (0.55) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL24233666 | 0.69 | PTPN11 (0.57) | PTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | PTPN18, PTPN7, PTPN1 | PTPN11 14/4885KCNH2 4775/4885MAPK3 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.